| Title |
The evolving role of tiotropium in asthma
|
|---|---|
| Published in |
Journal of Asthma and Allergy, August 2017
|
| DOI | 10.2147/jaa.s140577 |
| Pubmed ID | |
| Authors |
Emma R McIvor, R Andrew McIvor |
| Abstract |
Tiotropium is a long-acting muscarinic antagonist (LAMA) that exerts its bronchodilatory effect by blocking endogenous acetylcholine receptors in the airways. Its safety and efficacy are well established for the treatment of COPD, and it is now being recognized for its role in improving lung function and control in asthma. This review discusses the evolving role of tiotropium delivered by the Respimat(®) in patients across the range of asthma severities and ages, and provides an overview of safety and efficacy data. Tiotropium is the only LAMA currently approved for the treatment of asthma, and evidence from a large-scale clinical trial program, including several Phase III studies in adults, has demonstrated that tiotropium improves lung function and asthma control, with a safety profile comparable with that of placebo. Clinical trials in adolescent patients (aged 12-17 years) have also shown improvements in lung function and trends toward improved asthma control. Of note, the efficacy and safety profiles are consistent regardless of baseline characteristics and phenotype. Given the large and growing body of evidence, it is likely that as clinical experience with tiotropium increases, this treatment may possibly emerge as the key choice for add-on therapy to inhaled corticosteroids/long-acting β2-agonists, and in patients who do not tolerate long-acting bronchodilators or other medications, in the future. |
Mendeley readers
The data shown below were compiled from readership statistics for 29 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 29 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 21% |
| Other | 5 | 17% |
| Student > Postgraduate | 2 | 7% |
| Student > Master | 2 | 7% |
| Student > Bachelor | 1 | 3% |
| Other | 5 | 17% |
| Unknown | 8 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 52% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 7% |
| Nursing and Health Professions | 1 | 3% |
| Earth and Planetary Sciences | 1 | 3% |
| Neuroscience | 1 | 3% |
| Other | 0 | 0% |
| Unknown | 9 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 September 2017.
All research outputs
#20,447,499
of 23,002,898 outputs
Outputs from Journal of Asthma and Allergy
#416
of 463 outputs
Outputs of similar age
#276,916
of 317,424 outputs
Outputs of similar age from Journal of Asthma and Allergy
#4
of 4 outputs
Altmetric has tracked 23,002,898 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 463 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.1. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 317,424 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one.